Vertex Pharmaceuticals
VRTX
$473.09
+0.11%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for serious diseases, with a core focus on cystic fibrosis (CF) therapies such as Trikafta/Kaftrio, Kalydeco, and Alyftrek. As the undisputed market leader in CF, Vertex holds a near-monopoly position with a standard-of-care portfolio that generates billions in annual revenue. The current investor narrative centers on Vertex's strategic diversification beyond CF, driven by recent positive Phase 3 data for its APOL1-mediated kidney disease drug, the $10 billion acquisition of Crinetics Pharmaceuticals to bolster its endocrine pipeline, and expanding label opportunities for its gene therapy Casgevy and non-opioid painkiller Journavx.…
VRTX
Vertex Pharmaceuticals
$473.09
Related headlines
VRTX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $554.91 and implied upside of +17.3% versus the current price.
Average Target
$554.91
0 analysts
Implied Upside
+17.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$350 - $652
Analyst target range
Vertex is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating 1.63 on a 1-5 scale where 1 is Strong Buy). The average target price is $556.96, implying approximately 14.7% upside from the current price of $485.65. The distribution leans heavily bullish: the majority of ratings are Buy or Overweight, with only one Underperform (from Baird) and a few Hold ratings. Recent actions include reaffirmations of Buy/Outperform from Truist, UBS, RBC Capital, and Morgan Stanley, indicating sustained confidence. The target price range spans from a low of $350.00 to a high of $641.00. The high target of $641 assumes successful commercialization of the kidney drug and pain drug, plus continued CF market leadership, potentially driving earnings above $40 per share. The low target of $350 reflects a scenario where pipeline setbacks occur, CF growth stalls, or the Crinetics acquisition fails to deliver expected synergies. The wide spread ($291) signals high uncertainty around pipeline outcomes, which is typical for biotech. The consensus is bullish but not overly aggressive, with the average target suggesting moderate upside rather than a home run. The lack of recent downgrades and the steady stream of positive ratings reinforce the constructive outlook.
Bulls vs Bears: VRTX Investment Factors
Vertex presents a balanced risk/reward profile. The bull case is anchored by a dominant CF monopoly with exceptional margins, a fortress balance sheet, and a pipeline that could add $5B+ in new revenue from kidney drugs, Crinetics, and Casgevy. The bear case centers on CF growth deceleration, a premium valuation (29.3x P/E vs. 18x industry), and high pipeline execution risk. The single most important tension is whether Vertex's diversification efforts will succeed: if the kidney drug and Crinetics deliver, the stock could re-rate higher; if they fail, the premium multiple could compress significantly. Currently, the evidence slightly favors the bulls given the strong balance sheet and analyst consensus, but the margin of safety is thin.
Bullish
- Dominant CF Franchise with High Margins: Vertex's CF portfolio, led by Trikafta/Kaftrio ($2.35B Q1 revenue), generates 86.8% gross margins and 34.5% net margins, providing a stable cash flow base to fund pipeline expansion.
- Pipeline Diversification Catalysts: Positive Phase 3 data for APOL1 kidney drug and the $10B Crinetics acquisition (adding $5B potential revenue) could re-accelerate growth beyond CF, with FDA approval possible by year-end.
- Strong Balance Sheet and FCF: With $1.29B quarterly FCF, debt-to-equity of 0.21, and current ratio of 2.90, Vertex has ample liquidity to fund R&D ($962M/Q) and acquisitions without diluting shareholders.
- Analyst Consensus Bullish with Upside: 25 analysts rate it Buy (mean 1.63), with an average target of $556.96 implying 14.7% upside. The high target of $641 suggests potential for 32% gains if pipeline succeeds.
Bearish
- CF Market Maturation Slowing Growth: Revenue growth decelerated to 7.8% YoY in Q1 2026 from high-teens rates in 2022-2023, as the CF market approaches saturation. Trikafta faces eventual generic competition.
- Premium Valuation vs. Biotech Peers: Trailing P/E of 29.3x is 63% above the biotech industry average of ~18x, leaving little room for pipeline setbacks. The premium relies on continued execution.
- Pipeline Execution Risk is High: The $10B Crinetics acquisition (102% premium) and kidney drug success are not guaranteed. A Phase 3 failure could erase billions in market cap, as seen in biotech.
- Recent Underperformance vs. Market: Vertex's 1-year relative strength vs. SPY is -13.52%, indicating persistent underperformance. The stock is trading near its 52-week high but has lagged the broader rally.
VRTX Technical Analysis
Vertex is in a sustained uptrend, with the stock up 4.83% over the past year and currently trading at $485.65, which is 91% of its 52-week range ($362.50–$533.67). This positioning near the upper end of the range suggests strong momentum but also potential overextension, as the stock has rallied sharply from its April 2026 lows around $423. Short-term momentum is accelerating: the 1-month price change is +5.81% and the 3-month change is +10.07%, both outpacing the 1-year change, indicating a recent bullish catalyst. The 1-month relative strength vs. SPY is +5.50%, confirming outperformance. However, the 1-year relative strength is -13.52%, meaning Vertex has lagged the market over the longer term, suggesting the recent rally may be a catch-up move rather than a new secular trend. The 52-week high of $533.67 represents key resistance; a breakout above that level would signal a resumption of the long-term uptrend and likely attract momentum buyers. Support lies near the 52-week low of $362.50, but more immediate support is around $450 (the April 2026 lows). Beta is 0.292, indicating Vertex is significantly less volatile than the overall market—a 1% move in the S&P 500 corresponds to a 0.29% move in Vertex, making it a lower-risk holding within the biotech sector.
Beta
0.29
0.29x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$363-$534
Price range past year
Annual Return
-0.8%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | +1.0% | +0.6% |
| 3m | +9.9% | +3.4% |
| 6m | +1.0% | +7.1% |
| 1y | -0.8% | +16.4% |
| ytd | +4.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Vertex's revenue trajectory remains solidly growth-oriented, with Q1 2026 revenue of $2.99 billion, up 7.82% year-over-year. The trailing twelve-month revenue run-rate is approximately $12.3 billion, driven primarily by Trikafta/Kaftrio ($2.35 billion in Q1 2026) and Alyftrek ($424 million). Growth has been steady but decelerating from the high-teens rates seen in 2022–2023, as the CF market matures. The key growth drivers are new product launches: Casgevy, Journavx, and the kidney drug pipeline, which are expected to re-accelerate revenue growth in 2027–2028. Vertex is highly profitable, with Q1 2026 net income of $1.03 billion and a net margin of 34.5%. Gross margin is exceptionally high at 86.8%, typical for biotechnology companies with proprietary drugs. Operating margin of 38.1% reflects significant R&D spending ($962 million in Q1 2026, 32.2% of revenue), which is necessary for pipeline development but compresses near-term profitability. Margins have been stable over the past four quarters, with net margins ranging from 34.5% to 36.9%. Vertex boasts a fortress balance sheet: debt-to-equity is just 0.21, and the current ratio is 2.90, indicating ample liquidity. Free cash flow (FCF) was $1.29 billion in Q1 2026, and trailing twelve-month FCF is $3.71 billion, giving a FCF yield of 3.2% relative to market cap. ROE is 21.2%, reflecting strong capital efficiency. The company generates sufficient internal cash to fund both R&D and acquisitions, as evidenced by the $10 billion Crinetics deal, which will be funded from cash and debt capacity.
Quarterly Revenue
$3.0B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Since Vertex has positive net income ($1.03 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 29.3x, while the forward P/E is 22.8x, based on estimated EPS of $33.52 for 2026. The gap between trailing and forward P/E implies the market expects earnings growth of approximately 28% over the next year, driven by new product contributions and margin expansion. Compared to the biotechnology industry average P/E of roughly 18x (based on sector data), Vertex trades at a 63% premium. This premium is justified by Vertex's dominant CF franchise, high barriers to entry, strong pipeline optionality, and consistent profitability—attributes that many biotech peers lack. However, the premium also reflects the market's optimism about pipeline success, which carries execution risk. Historically, Vertex's trailing P/E has ranged from 14x (late 2021) to 48x (early 2025). The current 29.3x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The P/E was elevated in early 2025 due to a temporary earnings dip from R&D charges, but has since normalized. The current multiple is below the 5-year average of ~32x, indicating potential upside if growth re-accelerates.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Vertex's revenue concentration in CF (over 90% of sales) is a key risk, as Trikafta's growth is decelerating to 7.8% YoY. The $10 billion Crinetics acquisition at a 102% premium adds integration risk and could strain cash flows if pipeline milestones are missed. R&D spending at 32.2% of revenue is high, and any delay in new product launches would pressure margins. The company has no dividend, so total return depends entirely on capital appreciation.
Market & Competitive Risks: Vertex's trailing P/E of 29.3x is a 63% premium to the biotech industry average of 18x, making it vulnerable to multiple compression if growth disappoints. With a beta of 0.292, the stock is less correlated to the market, but its 1-year relative strength of -13.52% vs. SPY shows persistent underperformance. Competitive threats include potential generic CF drugs and rival gene therapies for sickle cell. Recent news highlights the Crinetics deal's high premium, which could weigh on sentiment if synergies fail to materialize.
Worst-Case Scenario: A Phase 3 failure for the kidney drug or Crinetics pipeline setbacks could trigger a sharp de-rating. The analyst low target of $350 implies a 28% downside from the current price of $485.65, aligning with the 52-week low of $362.50 (a 25% decline). In a severe scenario where CF growth stalls and pipeline fails, the stock could revisit the 52-week low, representing a potential loss of ~25-28% for investors.